Evidence map›Paper›PMID 33478622›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2021

The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases.

Maren Eggers, Ingeborg Schwebke, Miranda Suchomel, Valerie Fotheringham, Jürgen Gebel, Bernhard Meyer, Graziella Morace, Hans Joachim Roedger, Christine Roques, Pilar Visa and 1 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Disinfection methods against SARS-CoV-2: a systematic review.The Journal of hospital infection · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maren EggersLabor Prof Gisela Enders MVZ GbR, Stuttgart, Germany.
Ingeborg SchwebkeRobert Koch-Institute, Berlin, Germany.
Miranda SuchomelInstitute of Hygiene and Applied Immunology, Medical University, Vienna, Austria.
Valerie FotheringhamEvans Vanodine International PLC, Preston, United Kingdom.
Jürgen GebelInstitute for Hygiene and Public Health, University of Bonn, Germany.
Bernhard MeyerECOLAB Deutschland GmbH, Monheim, Germany.
Graziella MoraceIstituto Superiore di Sanità, Rome, Italy.
Hans Joachim RoedgerLysoform Dr. Hans Rosemann GmbH, Berlin, Germany.
Christine RoquesFaculté des sciences pharmaceutiques, Paul Sabatier University, Toulouse, France.
Pilar VisaEurofins BioPharma Product Testing Spain S.L.U, Barcelona, Spain.
Katrin SteinhauerSchülke & Mayr GmbH, Norderstedt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When facing an emerging virus outbreak such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a quick reaction time is key to control the spread. It takes time to develop antivirals and vaccines, and implement vaccination campaigns. Therefore, preventive measures such as rapid isolation of cases and identification and early quarantine of cases' close contacts-as well as masks, physical distancing, hand hygiene, surface disinfection and air control-are crucial to reduce the risk of transmission. In this context, disinfectants and antiseptics with proven efficacy against the outbreak virus should be used. However, biocidal formulations are quite complex and may include auxiliary substances such as surfactants or emollients in addition to active substances. In order to evaluate disinfectants' efficacy objectively, meaningful efficacy data are needed. Therefore, the European Committee for Standardisation technical committee 216 'Chemical disinfectants and antiseptics' Working Group 1 (medical area) has developed standards for efficacy testing. The European tiered approach grades the virucidal efficacy in three levels, with corresponding marker test viruses. In the case of SARS-CoV-2, disinfectants with proven activity against vaccinia virus, the marker virus for the European claim 'active against enveloped viruses', should be used to ensure effective hygiene procedures to control the pandemic.

Indexed as

Anti-Infective Agents, LocalCOVID-19DisinfectantsGuidelines as TopicHumansPandemicsPreventive MedicineSARS-CoV-2Virus DiseasesAnti-Infective Agents, LocalDisinfectantsCOVID-19disinfectantsemerging virusEuropean Standardisationhand hygieneinfection prevention and controloutbreakpandemicsurface disinfection

Identifiers

PMID33478622
PMCPMC7848678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.